|
[1]MOHD HANAFIAH K,GROEGER J,FLAXMAN AD,et al.Global epidemiology of hepatitis C virus infection:New estimates of agespecific antibody to HCV seroprevalence[J].Hepatology,2013,57(4):1333-1342．
|
|
[2]ZHANG Y,YAN XB.Current situation and problems of anti-hepatitis C virus therapy in era of direct-acting antiviral agents[J].World Chin J Dig,2017,25(13):1135-1142.(in Chinese)张莹，颜学兵．后DAA时代抗HCV治疗的现状及存在问题[J]．世界华人消化杂志，2017,25(13):1135-1142．
|
|
[3]ALRIC L,OLLIVIER-HOURMAND I,BRARD E,et al.Grazoprevir plus elbasvir in HCV genotype-1 or-4 infected patients with stage 4/5severe chronic kidney disease is safe and effective[J].Kidney Int,2018,94(1):206-213．
|
|
[4]FLAMM SL,BACON B,CURRY MP,et al.Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C:Retrospective analyses from the TRIO network[J].Aliment Pharmacol Ther,2018,47(11):1511-1522．
|
|
[5]HERNANDEZ-CONDE M,FERNNDEZ I,PERELLC,et al.Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection:Results from the Spanish HEPA-C real-world cohort[J].J Viral Hepat,2019,26(1):55-64．
|
|
[6] SORIA A,FAVA M,BERNASCONI DP,et al.Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort[J].Liver Int,2020,40(4):769-777．
|
|
[7] BUTT N,MUHAMMAD I,ABOU BAKR A,et al.Efficacy and safety of sofosbuvir-velpatasvir combination in hepatitis C virus-infected pakistani patients without cirrhosis or with compensated cirrhosis:Aprospective,open-label interventional trial[J].Cureus,2020,12(1):e6537．
|
|
[8] AASLD-IDSA HCV Guidance Panel.Hepatitis C guidance 2018 update:AASLD-IDSA recommendations for testing,managing,and treating hepatitis c virus infection[J].Clin Infect Dis,2018,67(10):1477-1492．
|
|
[9]HE CN,LI Y,GE H,et al.Clinical effect and safety of sofosbuvirbased regimens in treatment of hepatitis C virus-associated glomerulonephritis[J].J Clin Hepatol,2019,35(8):1714-1718.(in Chinese)贺彩妮，李彧，葛蘅，等．基于索磷布韦方案治疗HCV相关性肾小球肾炎的效果和安全性[J]．临床肝胆病杂志，2019,35(8):1714-1718．
|
|
[10]XU R,WANG M,CHEN QY,et al.The prevalence of mixed-genotype of HCV infections among chronic hepatitis C patients in China[J].Chin JViral Dis,2015,5(1):11-16.(in Chinese)许茹，王敏，陈秋宇，等．中国不同基因型/亚型丙型肝炎病毒混合感染率的研究[J]．中国病毒病杂志，2015,5(1):11-16．
|
|
[11] XIAO GR,XU T.Genotype distribution of 1998 strains of hepatitis Cvirus in west China hospital of Sichuan university from 2009 to 2013[J].J Sichuan Univ(Med Sci Edition),2016,47(5):755-758.(in Chinese)肖桂荣，徐珽．2009~2013年四川大学华西医院1998株丙型肝炎病毒基因分型研究[J]．四川大学学报(医学版)，2016,47(5):755-758．
|
|
[12]DU H,QI Y,HAO F,et al.Complex patterns of HCV epidemic in Suzhou:Evidence for dual infection and HCV recombination in East China[J].J Clin Virol,2012,54(3):207-212．
|
|
[13]FU Y,WANG Y,XIA W,et al.New trends of HCV infection in China revealed by genetic analysis of viral sequences determined from first-time volunteer blood donors[J].J Viral Hepat,2011,18(1):42-52．
|
|
[14] QIU P,CAI XY,DING W,et al.HCV genotyping using statistical classification approach[J].J Biomed Sci,2009,16:62．
|
|
[15]ABDELRAHMAN T,HUGHES J,MAIN J,et al.Next-generation sequencing sheds light on the natural history of hepatitis C infection in patients who fail treatment[J].Hepatology,2015,61(1):88-97．
|
|
[16] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for hepatitis C(2019 version)[J].J Clin Hepatol,2019,35(12):2670-2686.(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．丙型肝炎防治指南(2019年版)[J]．临床肝胆病杂志，2019,35(12):2670-2686．
|
|
[17] European Association for the Study of the Liver,European Association for the Study of the Liver.EASL recommendations on treatment of hepatitis C 2018[J].J Hepatol,2018,69(2):461-511.
|
DownLoad: